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Abstract  
Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator associated to diverse homeostatic and 
signaling roles. Enhanced biosynthesis of S1P, mediated by the sphingosine kinase isozymes (SK1 
and SK2), is implicated in several pathophysiological conditions and diseases, including skeletal 
muscle fibrosis, inflammation, multiple sclerosis and cancer. Therefore, therapeutic approaches that 
control S1P production have focused on the development of SK1/2 inhibitors. In this framework, we 
designed a series of natural monosaccharide-based compounds to enhance anchoring of the known 
SK1 inhibitor PF-543 at the polar head of the J-shaped substrate-binding channel. Herein, we describe 
the structure-based design and synthesis of new glycan-containing PF-543 analogues and we 
demonstrate their efficiency in a TGFβ1-induced pro-fibrotic assay. 
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Sphingosine 1-phosphate (S1P, Figure 1) has been considered for a long time merely an ultimate 
metabolite of sphingolipid breakdown. However, the identification of the ‘inside-out signaling’ 
mechanism associated with S1P production, release and activity, allowed to spotlight its key role as 
a bioactive signaling molecule which regulates many physiological processes as well as pathological 
ones.1,2 Intracellular S1P levels are tightly regulated by the crucial balance between its synthesis, 
mediated by two sphingosine kinase isozymes (SK1 and SK2), and reversible and irreversible 
degradation catalyzed by S1P phosphatases (SPP1 and SPP2) and S1P lyase respectively.3 
Specifically, SK1 and SK2 are expressed inside the cells where they show different subcellular 
localization that endow them with sometimes overlapping otherwise distinct biological effects. SKs 
catalyze ATP-dependent phosphorylation of sphingosine (Sph, Figure 1) inside the cells, and then 
S1P, besides to act as an intracellular mediator, can be exported in the extracellular milieu by means 
of unspecific ABC family members and specific spinster homologue 2 (SPNS2) transporters, where 
it interacts with its five specific GPCR receptors designated as S1PR1-5.4 Thus, SKs are key 
modulators of the dynamic S1P/sphingosine/ceramide ratio (sphingolipid rheostat model), which in 
turn affects cellular fate and the balance between cell survival and apoptosis.5 
The discovery of a link between dysregulation of S1P levels and the onset and progression of 
several pathological settings (e.g. cancer, autoimmune diseases, atherosclerosis, fibrosis) spotlighted 
SKs as potential targets for drug discovery.6,7 In this scenario, we focused on the role of SK1/S1P3 
axis in the onset of skeletal muscle fibrosis, the hallmark of musculoskeletal myopathies. 
Experimental data showed that the TGF1 cytokine-mediated up-regulation of SK1 is responsible for 
the induction of the fibrotic program in myoblasts.8 In addition, the remodeling of S1PR expression 
pattern occurs and it results in the increased expression of S1P3. Indeed, pharmacological as well as 
RNA interference approaches targeting SK1 or S1P3 dramatically altered the profibrotic effect 
induced by TGF1.8 Moreover, S1P signaling has been recognized as a new drug target in relapsing-
remitting multiple sclerosis. In this framework, a number of SK1 inhibitors have been developed to 
date.9-15 However, most of them are still limited by low potency and/or specificity, indicating the need 
for more performant SK1 inhibitors. Two possible strategies have recently emerged: i) the targeting 
of the less conserved SK1 allosteric sites, in order to increase inhibitor affinity and selectivity;9 ii) 
the integration of information from co-crystal structures of SK1 with known validated inhibitors14, 15 
into pharmacophoric models, with the aim to develop more potent inhibitors. 
 
 
Figure 1. Structures of Sphingosine (Sph), sphingosine 1-phosphate (S1P), PF-543, and the new 
glycoconjugates 1-Glc, 1-Gal and 1-GlcNAc.  
 
Conjugation of bioactive molecules with carbohydrates has emerged as a straightforward and 
promising approach to develop glycohybrids as source of new drug candidates.16-26 The 
glycoconjugation approach has been exploited for a wide range of structurally diverse drugs ranging 
from small organic molecules up to, more recently, macromolecules (e.g. proteins and antibodies).16,17 
This ‘sweet’ functionalization endow researchers to exploit new opportunities to improve both the 
targeting21,23,26 and the pharmacokinetic properties of hydrophobic drugs.18,19 In particular, 
glycosylation has been exploited as a promising strategy to improve the half-life of therapeutic 
peptides and proteins (such as somatostatin, opioid drugs to mention some of them)18-20 by inducing 
changes in their conformational structure and consequently in their physio-chemical properties. 
Moreover, the introduction of a glycan moiety has been exploited both to enforce specific tumor-
targeting of cytotoxic drugs,21 and to improve the related aqueous solubility of validated proteinases 
inhibitors.24,25 The growing scientific interest in this field has inspired us to investigate the use of 
glycans as the polar head group of SK1 inhibitors. To this end, we selected one of the most potent 
and selective SK1 inhibitor reported so far,14 PF-543, a non-lipid compound bearing 2-
hydroxymethylpyrrolidine as a ring-constrained isostere of the aminopropanediol group of the natural 
substrate (Figure 1). Specifically, it was demonstrated that the pyrrolidine ring provides hydrogen-
bonding interactions at the upper part of the cleft of the J-shaped pocket of the enzyme. In this work, 
we replaced the 2-hydroxymethylpyrrolidine moiety of PF-543 by selected monosaccharide units (i.e. 
D-glucose, N-Acetyl-D-glucosamine and D-galactose, Figure 1), with the aim to enhance the 
anchoring of the inhibitor at the J-shaped pocked of the enzyme by means of additional interactions 
provided by the sugar moiety. Herein, we describe the structure-based design and synthesis of 
monosaccharide-bearing PF-543 analogues SK1 inhibitors, and we provide evidence of their 
efficiency using a model of TGFβ1-induced skeletal muscle fibrosis. 
The design of the monosaccharide-bearing PF-543 analogues was based on the high-resolution 
crystal structure of SK1 in complex with the inhibitor PF-543.27 SK1 structure consists of an N-
terminal domain that binds ATP and a C-terminal domain that harbors the substrate-binding site 
(Figure 2A). The inhibitor bound inside the highly hydrophobic Sph-binding cavity, termed the “J-
channel” due to its shape, resembles the bent conformation of a lipid substrate (Figure 2B). The 
hydroxymethyl-pyrrolidine moiety of PF-543 occupies the position of a lipid’s head group next to 
the γ-phosphate of ATP,28 and it is anchored by two hydrogen bonds to the carboxylate group of 
Asp264. Remarkably, no other polar group of PF-543 was found to participate in hydrogen-bonding 
interactions within the J-channel.27 Still, the tight packing of the inhibitor at the hydrophobic pocket 
occupied by the terminal phenyl group (J-channel toe) and the placement of the sulfonylmethylene 
group at the heel of the J-channel (Figure 2B) has been proposed to confer the selectivity of PF-543 
for SK1 (IC50 = 25 nM) versus SK2 (IC50 >5,000 nM).
11 Now, considering that a glycan moiety at the 
head of the J-channel would offer the potential for additional polar interactions, we retained the 
hydrophobic moiety of PF-543, which could be fine-tuned at a later stage to modulate the selectivity 
profile for SK1/SK2, as demonstrated recently.11 
 Figure 2. A. Structure of SK1 with bound ADP and the inhibitor PF-543 inside the lipid binding channel. 
SK1 and PF-543 are taken from the crystal structure with PDB ID: 4V24,27 and the nucleotide by 
superimposing with PDB ID: 3VZD.28 B. Close-up view of the Sph-binding site, “J-channel”, illustrating the 
nonpolar residues (white stick-and-balls) that comprise the foot of the J-channel and the polar residues (green 
C, blue N, red O) around the polar head of the J-channel. PF-543 is shown with orange C sticks and dashed 
lines indicate the hydrogen bonding interactions with Asp264 (SK1 isoform 2 numbering as in PDB 4V24). 
Isoform-specific residue changes at the “toe” and “heel” of the J-channel have been proposed to influence 
inhibitor selectivity for SK1 versus SK2. C–E. Bound models of the designed analogues 1-Glc (C), 1-GlcNAc 
(D) and 1-Gal (E) inside the J-channel of SK1. The translucent surfaces indicate the space occupied by PF-
543, whereas polar residues at the head of the J-channel are shown with ball-and-sticks. Hydrogen bonds are 
indicated by dashed lines with the heavy-atom distance in Å, whereas putative interactions within 3.5 Å are 
shown with dotted lines. 
 
Indeed, our molecular docking calculations suggest that a β-D-glucopyranose moiety can be 
accommodated inside the Sph-binding site of SK1 without affecting the conformation of the 
hydrophobic moiety of PF-543 at the J-channel (Figure 2C). The selected bound conformation of 1-
Glc exhibits two hydrogen bonds between 6-OH and the backbone NH groups of Asn200 and Ala201. 
In addition, 2-OH of 1-Glc is within hydrogen-bonding distance from the side-chain of Asp264, albeit 
the geometry is not ideal (Figure 2C). This is also the case for the 6-OH of 1-Glc and the distal 
Glu275, as well as the 4-OH of 1-Glc and the carboxylate group of Asp167, which is located at the 
N-terminal domain of SK1. The N-acetyl glucosamine derivative 1-GlcNAc is predicted to interact 
with SK1 via hydrogen bonds of its amide NH with the carboxylate group of Asp264, and its acetyl 
C=O with the hydroxyl group of Ser254 (Figure 2D). Notably, Ser254 has been shown to interact 
with the polar head of the substrate,28 but not with PF-543.27 An additional H-bond could be formed 
by the 6-OH of 1-GlcNAc  and the amide group of Ala201, including potential interactions with the 
side-chains of Asp167 and Glu275, similar to 1-Glc. With the aim to investigate the role of the sugar 
stereochemistry at position C-4, we also employed β-D-galactose as a polar head. Our calculations 
suggest that the 6-OH and 4-OH of 1-Gal could be engaged in hydrogen bonding interactions with 
the hydroxyl group of Ser254 and the amide NH group of Gly428 (Figure 2E). The 3-OH group of 1-
Gal is also within hydrogen bonding distance from the side-chain of Asp167, however, at this bound 
pose there is no potential for direct interaction with Ala201, Asp264 or Glu275. Taken together, our 
analysis indicates that our design strategy is expected to yield analogues bearing the hydrophobic 
moiety of PF-543 that can be well accommodated within the J-channel of SK1. The introduction of 
a sugar moiety at the J-channel head endows the potential for additional hydrogen-bonding 
interactions with polar residues of SK1.  
Compounds 1-Glc, 1-Gal and 1-GlcNAc were synthesized following a convergent approach 
(Scheme 1). The hydrophobic scaffold 3 was prepared through an optimized procedure29 starting from 
commercially available 3-(bromomethyl)-5-methylphenyl acetate 2 (see SI, scheme S1). Compound 
3 was then used as the acceptor in the glycosylation reactions to give the target compounds 1 (Scheme 
1). In particular, the glucosyl 1-Glc and galactosyl 1-Gal derivatives were obtained through a 
glycosylation reaction between the per-pivaloylated glycosyl trichloroacetimidate donors (430 and 531 
respectively) and acceptor 3, followed by acyl deprotection through Zèmplen transesterification. In 
both cases the glycosylation reactions proceed in high yield and complete stereoselectivity, and 
compounds 6a and 6b were recovered as pure -glycosides (95% and 97% yield, respectively). A 
different strategy was used to prepare the N-acetyl D-glucosamine (GlcNAc) derivative 1-GlcNAc 
(Scheme 1). In this case, commercially available D-glucosamine penta-acetate 7 was reacted at high 
temperature with glycosyl acceptor 3 using ytterbium triflate as the catalyst to give 6c in satisfactory 
yield.32 Zemplén deacetylation of 6c with sodium methoxide in methanol gave efficiently (78%) the 
GlcNAc containing inhibitor 1-GlcNAc. 
 
 
Scheme 1. Synthesis of 1-Glc, 1-Gal, 1-GlcNAc and Ac-1-Glc. 
  
TGF‐β is involved in the regulation of skeletal muscle fibrosis as it was shown to be a potent 
inducer of myoblasts into myofibroblasts transdifferentiation,33 with a molecular mechanism relying 
on cytokine-mediated SK1 activation. On this basis, the ability of the new glycoconjugates to interfere 
with TGFβ1-induced fibrosis in C2C12 myoblasts was evaluated. PF-543 was used as reference 
control in this study at the concentration of 10 M according with data in the literature.34-36 Cells 
were incubated with 10 µM of the inhibitors (e.g. PF-543, 1-Gal, 1-GlcNAc and 1-Glc) for 30 min 
before the addition of the 5.0 ng/mL solution of TGFβ1. The expression of protein markers that 
correlate with muscle fibrosis were evaluated by western blot analysis using specific anti-α-SMA and 
anti-SMα22. Total cell lysates were subjected to western blot analysis to measure the relative content 
of fibrosis markers. In agreement with previous data,8 48 h TGFβ1 treatment induced the expression 
of fibrosis markers (Figure 3). Subsequently, treatment with PF-543 (10 µM) resulted in abrogation 
of the α-SMA expression induced by TGFβ1 whereas the expression of SMα22 was significantly 
affected (Figure 3). The three glycoconjugates (1-Glc, 1-Gal and 1-GlcNAc) displayed a variable 
effect according with the glycan residue (Figure 3). Both the α-SMA and SMα22 expression induced 
by TGFβ1 were not affected by 1-Gal, while 1-GlcNAc displayed a partial inhibition of α-SMA 
expression. Notably, 1-Glc significantly affected both the α-SMA and SMα22 expression induced by 
TGFβ1, an effect comparable to that displayed by PF-543 (Figure 3). 
  
Figure 3. Effect of glycoconjugates 1-Glc, 1-Gal and 1-GlcNAc compared to PF-543 on TGFβ1-induced 
fibrosis marker expression in murine myoblasts. C2C12 myoblasts were seeded to 80% confluence and 
challenged with 5.0 ng/mL TGFβ1, PF-543, 1-Gal, 1-GalNAc and 1-Glc (30 min, 10 µM). A. The expression 
of protein markers which expression correlates with muscle fibrosis, has been evaluated by western blot 
analysis, using specific anti-α-SMA and anti-SMα22. A representative blot is shown among three independent 
experiments with analogous results. B. and C. Densitometric analysis was performed of three independent 
experiments and data, normalized to β-actin expression, were reported as mean ± SD of fold change above 
control untreated. The effect of TGFβ1 on fibrosis marker expression was significant by student t-test ** 
P<0.01 ***P<0.001. The effect of pharmacological inhibition of SK1 on TGFβ1 induced fibrosis marker 
expression was significant by two-way ANOVA followed by Bonferroni post-hoc test. # P<0.05, ##P<0.01, 
###P<0.001. 
 
Considering that acetylation of the hydroxyl groups of glycans has been proved to be an efficient 
approach to promote transit of glycan containing molecules across the plasma membrane,37 we also 
sought to investigate the activity of the per-acetylated derivative of 1-Glc, Ac-1-Glc (Scheme 1, see 
SI). Therefore, a dose dependence of 1-Glc and Ac-1-Glc compared to the parental drug PF-543 on 
TGFβ1-induced fibrosis of murine myoblasts was performed in order to define the bioactive 
concentration. Western blot data (see SI, Figure S1) confirmed that 10 M resulted in the most 
effective concentration on affecting the expression of both α-SMA and SMα22. Then, western blot 
analysis was performed to detect the relative expression of fibrosis markers induced by TGFβ1 after 
30 min and 2 h treatments with 1-Glc, Ac-1-Glc and PF-543 as control (Figure 4). The TGFβ1-
induced α-SMA expression was completely abrogated by Ac-1-Glc after 30 min, whereas the 
expression of SMα22 was significantly decreased after 2 h treatment (Figure 4). Notably, the effect 
of pharmacological inhibition of TGFβ1 induced α-SMA expression after 30 min Ac-1-Glc treatment 
was significantly higher compared to 1-Glc (two-way ANOVA followed by Bonferroni post-hoc test, 
§§ P<0.01, Figure 4), supporting our rationale. 
 
 
Figure 4. Effect of 1-Glc and Ac-1-Glc compared to PF-543 in TGFβ1-induced fibrosis marker expression 
in murine myoblasts. C2C12 myoblasts were seeded to 80% confluence and treated with 5 ng/mL TGFβ1, PF-
543, 1-Glc and Ac-1-Glc (30 min, 120 min). A. The expression of protein markers which expression correlates 
with muscle fibrosis, has been evaluated by western blot analysis, using specific anti-α-SMA and anti-SMα22. 
A representative blot is shown among three independent experiments with analogous results. B. and C. 
Densitometric analysis was performed of three independent experiments and data, normalized to β-actin 
expression, were reported as mean ± SD of fold change above control untreated. 
The effect of pharmacological inhibition of SK1 on TGFβ1 induced fibrosis marker expression was significant 
by two-way ANOVA followed by Bonferroni post-hoc test. # P<0.05, ##P<0.01, ###P<0.001. The effect of 
pharmacological inhibition of SK1 by 30 min Ac-1-Glc compared to 1-Glc on TGFβ1 induced αSMA 
expression was significant by two-way ANOVA followed by Bonferroni post-hoc test. §§ P<0.01. 
 
Laser scanning confocal microscopy was employed to outline the distribution of fibrosis markers 
that are functional cytoskeletal proteins, whose expression can be analyzed to follow the onset and 
progression of skeletal muscle fibrosis. Confocal immunofluorescence analysis revealed an enhanced 
expression of αSMA in C2C12 cells treated with 5.0 ng/mL TGFβ1 for 48 h, which resulted mainly 
localized within F-actin microfilaments (Figure 5). In agreement with previous results, the treatment 
with PF-543 as well as 1-Glc and Ac-1-Glc (10 µM) completely prevented the cytokine-induced 
expression of αSMA (Figure 5). 
 
 
Figure 5 Confocal immunofluorescence analysis was performed in 24 h serum-starved C2C12 cells that were 
treated with 5 ng/mL TGFβ1, after a 2 h of incubation with PF-543, 1-Glc and Ac-1-Glc. Anti-αSMA primary 
antibody and fluorescein-conjugated anti-mouse secondary antibody were used. DAPI was added to label 
nuclei and rhodamine-phalloidin as high-affinity F-actin probe in order to trace cytoskeletal microfilaments. 
The immunofluorescence images shown are representative of 6 fields for each condition. 
 
It has been extensively demonstrated that TGF‐β family members are implicated in the regulation 
of myogenic differentiation as they were shown to be potent inhibitors of myoblasts differentiation. 
Exogenous TGFβ1 was shown to prevent features of skeletal muscle differentiation, such as fusion 
and myotube formation, in different cultured cell lines in vitro,38, 39  and the molecular mechanism at 
least in part rely on SK1 activation by the cytokine.8 For this reason, 1-Glc and Ac-1-Glc conjugates 
were assayed for the effect on TGFβ1-mediated myoblast differentiation compared to PF-543. For 
this purpose, western blot analysis was performed to measure the relative expression of caveolin-3 
(Cav-3) by TGFβ1 after 30 min, 1 h and 2 h incubation with PF-543, 1-Glc and Ac-1-Glc 
glycoconjugates. Data (see SI, Figure S2) showed that, as expected, TGFβ1 decreases skeletal muscle 
differentiation whereas this effect was significantly reverted by both 1-Glc, Ac-1-Glc and it was 
almost completely abolished at 2 h of incubation.  
Taken together our findings suggest that the glucose-bearing derivative and in particular its 
acetylated form Ac-1-Glc, is the most active compound, as it completely abrogates the TGFβ1 
induced expression of a key fibrosis marker. Although additional structural and biochemical 
information are required, we can hypothesize that the lower potency of 1-Gal compared to 1-Glc and 
1-GlcNAc is due to the lack of interaction with the side-chain of Asp264 (Figure 2C-E), a key residue 
that has been shown to provide the only hydrogen-bonding interactions of PF-543 within the J-
channel of SK1. In conclusion, our work demonstrates that the use of natural monosaccharides as the 
polar head-group of known SK inhibitors offers the potential to develop a new class of signaling 
molecules that regulate the expression of fibrosis markers. The biological effects of the new PF-543 
analogues on TGF1-profibrotic effects in myoblasts suggest a possible interaction and inhibition of 
the catalytic site of SK1. However, further studies (e.g. binding data and further biochemical and 
pharmacological characterizations) are needed to corroborate this hypothesis. Finally, considering the 
sugar heterogeneity in terms of stereochemistry and availability of functional groups, our findings 
suggest that glycans can be employed as an additional tool to explore the pharmacological profile of 
modulators of the sphingolipid rheostat model. 
 
 
Experimental section 
Generals: Standard laboratory procedures were followed to carry out the reactions and to prepare 
dry solvents. Optical rotations were measured with a Perkin-Elmer 241 polarimeter at 20 °C. 1H 
and 13C NMR spectra were recorded with a Bruker AVANCE-500 spectrometer at a sample 
temperature of 298 K. High-resolution mass spectra were collected by electrospray ionization 
(ESI) spectroscopy on a QTof SYNAPT G2Si Mass Spectrometer.  
 
4-[(3-Methyl-5-(phenylsulfonylmethyl)-phenoxy)methyl]-phenylmethyl -D-glucopyranoside 
(1-Glc)  
To a stirred solution of compound 6a (0.25 g, 0.028 mmol) in DCM (0.5 mL) sodium methoxide in 
methanol (0.1 M solution, 0.56 mL) was added. The reaction was stirred at room temperature, and 
further portions of sodium methoxide (0.1 M solution, 0.30 mL) were added every 12 h. After 24 h 
the reaction was neutralized with an ion exchange resin (Dowex 50 × 8, H+ form), filtered and 
concentrated. The crude product was subjected to flash chromatography (DCM/MeOH, 9:1) to give 
pure 1-Glc (0.012 g, 80%) as an amorphous white solid. []D20 = -32.0 (c = 0.5 in chloroform). 1H 
NMR (CDCl3/CD3OD, 2:1):  = 7.68-7.62 (m, 3H, arom.), 7.53-7.47 (m, 2H, arom.), 7.44-7.39 (m, 
2H, arom.), 7.37-7.33 (m, 2H, arom.), 6.74 (br s, 1H, arom.), 6.49 (br s, 1H, arom.), 6.48 (br s, 1H, 
arom.), 4.96-4.92 (m, 3H, OCHaHb and CH2SO2), 4.68 (d, 1H, J = 11.8 Hz, OCHaHb), 4.38 (d, 1H, 
J1,2 = 7.7 Hz, H-1), 4.28 (s, 2H, PhCH2O), 3.88 (dd, 1H, J5,6a = 2.7 Hz, J6a,6b = 12.0 Hz, H-6a), 3.74 
(dd, 1H, J5,6b = 5.3 Hz, J6a,6b = 12.0 Hz, H-6b), 3.43-3.35 (m, 2H, H-3,4), 3.35-3.26 (m, 2H, H-2,5), 
2.20 (s, 3H, CH3). 
13C NMR (CDCl3/CD3OD, 2:1):  = 158.6, 139.7, 137.6, 137.2, 136.4, 133.8, 
128.9-127.4 (9C), 124.4, 116.4, 114.0, 102.0 (C-1), 76.6, 76.2 (C-5), 73.6 (C-2), 70.6 (OCH2), 70.3, 
69.6 (CH2SO2), 62.6 (PhCH2O), 61.7 (C-6), 20.9 (CH3). HRMS (ESI): m/z calcd for C28H32O9NaS 
567.1665 [M+Na]+, found 567.1665. 
 
Supporting Information The Supporting Information is available free of charge on the ACS 
Publications website at DOI: XXXXX. Figures S1 and S2. Synthetic procedures for the synthesis of 
compounds 3, 6a-c, 1-Gal, 1-GlcNAc, and Ac-1-Glc. Computational and biological methods. 1H and 
13C spectra of new compounds. Coordinate files of the SK1–glycoconjugate models in PDB format. 
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